Story perspectives

Revolutionary CAR T-Cell Therapy Boosts Cancer Remission Rates

8/29/2025

Summary

Story summary

AdventHealth in Orlando now offers outpatient CAR T-cell therapy, enhancing recovery and treatment outcomes.
One patient achieved full remission from myeloma, demonstrating the therapy's effectiveness.
Over 80% of acute leukemia patients remain undetectable post-treatment, according to Roswell Park Comprehensive Cancer Center.
A NEJM case study highlights successful targeted treatment for secondary lymphoma after CAR T-cell therapy.
The FDA has approved CAR T-cell therapy for mantle cell lymphoma, broadening patient treatment options.

1 of 1

Story summary

AdventHealth in Orlando now offers outpatient CAR T-cell therapy, enhancing recovery and treatment outcomes.
One patient achieved full remission from myeloma, demonstrating the therapy's effectiveness.
Over 80% of acute leukemia patients remain undetectable post-treatment, according to Roswell Park Comprehensive Cancer Center.
A NEJM case study highlights successful targeted treatment for secondary lymphoma after CAR T-cell therapy.
The FDA has approved CAR T-cell therapy for mantle cell lymphoma, broadening patient treatment options.